MassBio CEO & President Kendalle Burlin O’Connell originally posted this update to LinkedIn.
The lame-duck session is underway and a new Congress is set for January with Democrats taking control of both the House and Senate. Key leaders are already laying early groundwork for oversight of recent Trump Administration drug pricing deals. Meanwhile, the administration is pushing to confirm a new FDA commissioner before the Senate changes hands and NIH proposed some of its most significant updates in years to how clinical research is funded and monitored, and the WuXi AppTec reversal is a reminder that the rules governing U.S.–China biotech ties are still in flux.
Congressional Democrats Demand Disclosure of MFN Drug Pricing Agreements: Senior Democratic lawmakers have requested unredacted copies of the Trump administration’s most-favored-nation pricing agreements from all 27 participating pharmaceutical manufacturers. The requests represent a concrete step toward expanded congressional scrutiny of the administration’s drug pricing arrangements, which are likely to see significant attention when the new Congress convenes in January.
NIH Proposes Changes to Clinical Research Oversight Requirements: NIH is seeking public comment on proposed revisions to its data and safety monitoring policy, which has not been comprehensively updated since 1998. The proposal would extend monitoring requirements beyond clinical trials to all NIH-supported clinical research, while adopting a more risk-based approach intended to reduce unnecessary administrative burdens. Notably, the changes would eliminate the blanket requirement for Data and Safety Monitoring Boards for all Phase III and multisite clinical trials, allowing monitoring requirements to be tailored to individual study risks. The proposal could affect how academic research institutions and clinical investigators manage federally funded studies. Public comments are due January 6, 2027.
NIH Moves to Streamline Clinical Trial Funding Opportunities: On November 10, NIH announced plans to reorganize its clinical trial funding opportunities around the type of study being conducted rather than specific diseases or scientific topics. The new framework would establish broader funding announcements covering early-stage trials, multisite studies, pragmatic trials, and clinical research networks, with more consistent application requirements across NIH institutes. NIH says the changes are intended to simplify the funding process, reduce administrative complexity, and improve coordination across research programs. The transition will be implemented in phases, with implications for Massachusetts academic medical centers, research institutions, and investigators seeking federal support for clinical studies.
White House Pushes to Confirm FDA Commissioner: The Trump administration is accelerating efforts to confirm Heidi Overton as FDA commissioner before Democrats assume control of the Senate in January. Overton faces a narrowing confirmation window and concerns from key Republican senators, including Senate HELP Committee Chairman Bill Cassidy, who met with her this week. A hearing could be set for as early as next week.
Pentagon Removes WuXi AppTec from List of Chinese Military Companies: On November 10, the Department of Defense formally removed WuXi AppTec from its Section 1260H list of Chinese military companies, following an August federal court ruling that blocked enforcement of the designation. WuXi had been added to the list in June. The decision carries important implications for implementation of the BIOSECURE Act, which restricts federal procurement and funding involving designated biotechnology companies of concern. While WuXi AppTec’s removal reduces its immediate regulatory exposure, the Pentagon has reserved the right to relist the company, and the administration is expected to publish its list of biotechnology companies of concern by December 18. The development underscores continued uncertainty surrounding U.S.–China biotechnology restrictions and their potential implications for domestic drug development.
